Clearpoint Neuro Stock Performance
CLPT Stock | USD 5.51 0.18 3.38% |
The firm shows a Beta (market volatility) of 2.97, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Clearpoint Neuro will likely underperform. Clearpoint Neuro has an expected return of -0.32%. Please make sure to confirm Clearpoint Neuro jensen alpha, as well as the relationship between the skewness and day median price , to decide if Clearpoint Neuro performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Clearpoint Neuro has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in May 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 3.57 | Five Day Return 0.001812 | Year To Date Return (18.34) | Ten Year Return (88.96) | All Time Return (81.60) |
Last Split Factor 1:40 | Dividend Date 2016-07-27 | Last Split Date 2016-07-27 |
1 | Payment of 10 shares by Stigall L Jeremy of Clearpoint Neuro subject to Rule 16b-3 | 02/23/2024 |
2 | ClearPoint Neuro Launches Proposed Public Offering of Common Stock | 02/28/2024 |
3 | ClearPoint Neuro reports positive laser therapy results | 03/11/2024 |
4 | ClearPoint Neuro, Inc. Reports Q4 Loss, Tops Revenue Estimates | 03/12/2024 |
5 | ClearPoint Neuro Full Year 2023 Earnings Beats Expectations | 03/14/2024 |
6 | ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstazaas a Treatment for AADC ... | 03/19/2024 |
7 | ClearPoint Neuro Trading Down 3 percent - Defense World | 03/26/2024 |
8 | Acquisition by Richards Timothy T. of 1640 shares of Clearpoint Neuro at 6.8 subject to Rule 16b-3 | 04/01/2024 |
9 | Disposition of 1730 shares by Stigall L. Jeremy of Clearpoint Neuro at 6.53 subject to Rule 16b-3 | 04/15/2024 |
10 | ClearPoint Neuro feliciteert partner AviadoBio met de behandeling van de eerste patint in klinisch onderzoek ASPIRE-FTD, waarin AVB-101 wordt gevalueerd voor fr... | 04/17/2024 |
11 | Is There Now An Opportunity In ClearPoint Neuro, Inc. | 04/19/2024 |
Begin Period Cash Flow | 27.6 M |
Clearpoint |
Clearpoint Neuro Relative Risk vs. Return Landscape
If you would invest 714.00 in Clearpoint Neuro on January 24, 2024 and sell it today you would lose (163.00) from holding Clearpoint Neuro or give up 22.83% of portfolio value over 90 days. Clearpoint Neuro is currently does not generate positive expected returns and assumes 4.494% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Clearpoint, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Clearpoint Neuro Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clearpoint Neuro's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Clearpoint Neuro, and traders can use it to determine the average amount a Clearpoint Neuro's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0707
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | CLPT |
Estimated Market Risk
4.49 actual daily | 39 61% of assets are more volatile |
Expected Return
-0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Clearpoint Neuro is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clearpoint Neuro by adding Clearpoint Neuro to a well-diversified portfolio.
Clearpoint Neuro Fundamentals Growth
Clearpoint Stock prices reflect investors' perceptions of the future prospects and financial health of Clearpoint Neuro, and Clearpoint Neuro fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clearpoint Stock performance.
Return On Equity | -0.76 | ||||
Return On Asset | -0.29 | ||||
Profit Margin | (0.92) % | ||||
Operating Margin | (0.69) % | ||||
Current Valuation | 134.58 M | ||||
Shares Outstanding | 27.07 M | ||||
Price To Earning | (3.36) X | ||||
Price To Book | 7.44 X | ||||
Price To Sales | 6.57 X | ||||
Revenue | 23.95 M | ||||
Gross Profit | 13.53 M | ||||
EBITDA | (20.99 M) | ||||
Net Income | (22.09 M) | ||||
Cash And Equivalents | 45.14 M | ||||
Cash Per Share | 1.84 X | ||||
Total Debt | 13.94 M | ||||
Debt To Equity | 0.28 % | ||||
Current Ratio | 10.33 X | ||||
Book Value Per Share | 0.86 X | ||||
Cash Flow From Operations | (13.72 M) | ||||
Earnings Per Share | (0.90) X | ||||
Market Capitalization | 144.28 M | ||||
Total Asset | 42.66 M | ||||
Retained Earnings | (172.46 M) | ||||
Working Capital | 28.74 M | ||||
Current Asset | 8.1 M | ||||
Current Liabilities | 1.85 M | ||||
About Clearpoint Neuro Performance
To evaluate Clearpoint Neuro Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Clearpoint Neuro generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Clearpoint Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Clearpoint Neuro market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Clearpoint's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 279.23 | 407.41 | |
Return On Tangible Assets | (0.53) | (0.56) | |
Return On Capital Employed | (0.64) | (0.67) | |
Return On Assets | (0.52) | (0.54) | |
Return On Equity | (1.04) | (0.99) |
Things to note about Clearpoint Neuro performance evaluation
Checking the ongoing alerts about Clearpoint Neuro for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clearpoint Neuro help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Clearpoint Neuro generated a negative expected return over the last 90 days | |
Clearpoint Neuro has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 23.95 M. Net Loss for the year was (22.09 M) with profit before overhead, payroll, taxes, and interest of 13.53 M. | |
Clearpoint Neuro currently holds about 45.14 M in cash with (13.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
Clearpoint Neuro has a poor financial position based on the latest SEC disclosures | |
Latest headline from finance.yahoo.com: Is There Now An Opportunity In ClearPoint Neuro, Inc. |
- Analyzing Clearpoint Neuro's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clearpoint Neuro's stock is overvalued or undervalued compared to its peers.
- Examining Clearpoint Neuro's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clearpoint Neuro's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clearpoint Neuro's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clearpoint Neuro's stock. These opinions can provide insight into Clearpoint Neuro's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearpoint Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Clearpoint Stock analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Clearpoint Neuro's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearpoint Neuro. If investors know Clearpoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearpoint Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.974 | Quarterly Revenue Growth 0.316 | Return On Assets (0.29) | Return On Equity (0.76) |
The market value of Clearpoint Neuro is measured differently than its book value, which is the value of Clearpoint that is recorded on the company's balance sheet. Investors also form their own opinion of Clearpoint Neuro's value that differs from its market value or its book value, called intrinsic value, which is Clearpoint Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearpoint Neuro's market value can be influenced by many factors that don't directly affect Clearpoint Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearpoint Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearpoint Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearpoint Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.